A. Justin Lampropoulos: What It Takes to Make MedTech Work at Scale

In an industry increasingly shaped by regulatory pressure, cost constraints, and supply-chain fragility, SYNDEO Medical, led and founded by A. Justin Lampropulos, has taken an uncommon path. While many medical-device companies have responded by simplifying their offerings or narrowing their scope, SYNDEO has chosen instead to lean into complexity; re-engineering procedural solutions to reflect how interventional care is actually delivered.

Since Business Worldwide Magazine last profiled the company in 2023, the company has undergone a period of intensive, foundational growth. Having secured full European MDR approval across its flagship platforms, SYNDEO has now expanded operations into more than 30 countries, and launched close to a dozen new products. 

Much of the last two years has been spent embedding regulatory discipline, strengthening quality systems, and validating that SYNDEO’s operating model could withstand sustained regulatory and operational pressure. That work culminated in MDR approval for the SYNDEOPack™ Interventional Procedure Pack and Xssential™ Rapid Delivery Procedure Packs, marking a defining milestone in the company’s evolution.

Redefining the Procedure Pack

At the core of SYNDEO’s approach is a redefinition of what a procedure pack should be. Rather than offering partial bundles that exclude everyday-use devices, the company designs packs around what clinicians genuinely need in the procedure room. This delivers significant benefits in efficiency, cost control and waste production. By openly integrating everyday devices into the procedure pack, SYNDEO reduces fragmentation; fewer individual items need to be sourced, opened, and discarded, and the risk of last-minute substitutions is significantly reduced. The result is a procedural solution aligned with real-world clinical workflows rather than catalogue convenience.

This philosophy was recently reinforced during a discussion with a senior clinician, whose request captured the challenge SYNDEO set out to solve. As Lampropulos recalls:

“What we are solving for is readiness and consistency. Clinicians don’t want partial solutions. They want partners willing to carry the complexity so they don’t have to.”

The decision to launch SYNDEO Medical came at a time when many organisations were stepping back from the interventional procedure-pack market. Regulatory requirements were intensifying, margins were tightening, and operational risk was increasing. For many companies, contraction was a rational response.

However, Lampropulos and his team were hearing a different message from clinicians and procurement teams. As established solutions disappeared, customers repeatedly asked where they could turn to replicate what had quietly been lost. At the same time, a broader disconnect became increasingly evident. While interventional medicine advanced rapidly through new therapeutic devices and techniques, the procedural tools supporting those innovations remained largely unchanged and were often based on designs that are decades old.

Building for Compliance and Scale

SYNDEO was founded on the belief that the procedure itself deserved the same level of innovation as the devices being deployed within it. By treating procedural solutions as systems rather than collections of parts, and by investing early in the regulatory and quality infrastructure required to support that approach, the company identified an opportunity in a segment many had overlooked.

Balancing agility with stringent regulatory requirements has required deliberate structural choices. Rather than attempting to invent or manufacture every component internally, SYNDEO partners with best-in-class technology providers and integrates those capabilities into its final solutions. Crucially, accountability is never outsourced. The company retains full responsibility for system performance, quality, and regulatory compliance, allowing it to remain lean without sacrificing control.

This balance was tested most visibly during the European MDR process. Achieving approval for SYNDEOPack™ and Xssential™ required robust design control, rigorous risk management, and comprehensive supplier oversight. MDR left little room for interpretation or compromise, demanding absolute execution at every level of the organisation.

The successful outcome proved transformational. MDR approval not only unlocked growth but established credibility, demonstrating that SYNDEO could navigate uncertainty and complexity while delivering compliant, high-quality solutions at scale.

Sustainability has also become a defining pillar of the company’s strategy. Procedure packs, when designed correctly, offer one of the most practical opportunities to reduce environmental impact in interventional care. Consolidation alone drives meaningful reductions in packaging waste, sterilisation cycles, and transport demands.

SYNDEO has gone further by embedding eco-conscious components across its packs, selected for demonstrated biodegradability performance. Importantly, sustainability is treated as a baseline responsibility rather than an optional feature. These components are included as standard, even when they carry a marginal cost premium, ensuring environmental considerations are built into the product rather than added later.

Innovation Beyond Headline Devices

Customer-driven innovation continues to shape SYNDEO’s development pipeline. A clear example is the upcoming SATURN2 platform, which modernises high-pressure inflation devices; tools used daily in interventional labs but largely untouched by innovation for decades. Redesigned from first principles, SATURN2 offers improved pressure control, rapid inflation capability, and consistent performance under demanding conditions.

This focus reflects SYNDEO’s broader view that meaningful innovation in med-tech is not limited to breakthrough implants or headline technologies. Upgrading the procedural ecosystem that supports those innovations can deliver equally significant clinical and operational benefits.

When Systems Become the Advantage

Today, SYNDEO operates across more than 20 specialties and over 30 countries. Scaling globally has required a partnership-driven approach, working with local and regional organisations that understand clinical practice patterns, regulatory nuance, and market dynamics. Alignment on quality, ambition, and execution standards has been essential to maintaining consistency while allowing for regional flexibility.

The company’s recent global distribution agreement for the Passio Pump Drainage System illustrates how SYNDEO’s portfolio is evolving. While it represents a move beyond core procedure packs, it remains firmly aligned with the company’s procedural focus. By integrating more advanced, digitally enabled technologies with its foundational platforms, SYNDEO is extending its role within the procedural ecosystem rather than diluting its strategy.

Looking ahead, Lampropulos sees companies like SYNDEO playing an increasingly central role as healthcare systems face mounting pressure around cost efficiency, regulatory compliance, supply-chain resilience, and environmental responsibility. Fragmented purchasing models are giving way to system-level thinking, and procedural partners capable of reducing friction across multiple dimensions are becoming essential.

Reflecting on SYNDEO’s mission to connect people, products, and purpose, Lampropulos defines success in terms of trust and impact rather than scale alone:

“If five years from now clinicians trust us, partners respect us, and healthcare systems depend on us to quietly improve how care is delivered every day, then we will have done what we set out to do.”

SYNDEO’s journey remains at an early stage, but its foundations are intentionally built to endure. By leaning into complexity, investing early in regulatory and quality discipline, and modernising overlooked aspects of procedural care, the company is demonstrating that in modern med-tech, execution—done properly—remains the ultimate competitive advantage.